GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Nasdaq  -  04:00 2022-06-27 pm EDT
62.83 USD   -0.40%
04:57pGilead Sciences Resubmits Application for HIV Treatment Candidate
MT
04:31pGilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
BU
10:43aGilead Sciences, Inc. - Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Piper Sandler Adjusts Gilead Sciences' Price Target to $69 From $73, Maintains Neutral Rating

05/17/2022 | 05:09am EDT


© MT Newswires 2022
All news about GILEAD SCIENCES, INC.
04:57pGilead Sciences Resubmits Application for HIV Treatment Candidate
MT
04:31pGilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapa..
BU
10:43aGilead Sciences, Inc. - Investigational Lenacapavir Receives Positive CHMP Opinion for ..
AQ
09:04aGilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Negle..
BU
06/24Gilead Sciences Receives Positive CHMP Opinion for HIV Drug
MT
06/24Gilead Sciences, Inc. - Treatment With Hepcludex (Bulevirtide) Meets Primary Endpoint a..
AQ
06/24Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug R..
BU
06/24Gilead Sciences, Inc. Announces Investigational Lenacapavir Receives Positive Chmp Opin..
CI
06/24Gilead Gets CHMP Backing for Lenacapavir in Multi-Drug Resistant HIV
DJ
06/23Gilead Sciences Says Phase 3 Trial of Hepatitis Drug Meets Primary Endpoint
MT
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 24 543 M - -
Net income 2022 4 227 M - -
Net Debt 2022 16 327 M - -
P/E ratio 2022 17,8x
Yield 2022 4,62%
Capitalization 78 809 M 78 809 M -
EV / Sales 2022 3,88x
EV / Sales 2023 3,80x
Nbr of Employees 14 400
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 62,83 $
Average target price 69,65 $
Spread / Average Target 10,9%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-12.75%44 742
BIONTECH SE-48.01%32 574
GENMAB A/S-15.13%20 738